348 related articles for article (PubMed ID: 30923995)
41. Clinical associations of BRAF and MAP2K1 mutations in pediatric Langerhans cell histiocytosis: When 1 + 1 = 3.
Kemps PG; van den Bos C; van Halteren AGS;
Am J Hematol; 2023 Sep; 98(9):E244-E246. PubMed ID: 37357851
[No Abstract] [Full Text] [Related]
42. ddPCR Analysis Reveals BRAF V600E Mutations Are Infrequent in Isolated Pituitary Langerhans Cell Histiocytosis Patients.
Nellan A; Bodlak A; Mirsky DM; Mulcahy Levy J; Garrington TP; Foreman NK; Gilani A; Hayashi M
J Neuropathol Exp Neurol; 2020 Dec; 79(12):1313-1319. PubMed ID: 32930721
[TBL] [Abstract][Full Text] [Related]
43. A Case of Pulmonary Langerhans Cell Histiocytosis with BRAF V600E-negative and MAP2K1-posivtive Mutations Presenting as Diffuse Nodules in Chest High-resolution Computed Tomography After Smoking Cessation.
Li Y; Cai HR; Ma M; Wang LJ; Yang J; Ding JJ; Miao LY
Chin Med J (Engl); 2016 Jun; 129(11):1384-6. PubMed ID: 27231182
[No Abstract] [Full Text] [Related]
44. BRAF V600E mutation in Juvenile Xanthogranuloma family neoplasms of the central nervous system (CNS-JXG): a revised diagnostic algorithm to include pediatric Erdheim-Chester disease.
Picarsic J; Pysher T; Zhou H; Fluchel M; Pettit T; Whitehead M; Surrey LF; Harding B; Goldstein G; Fellig Y; Weintraub M; Mobley BC; Sharples PM; Sulis ML; Diamond EL; Jaffe R; Shekdar K; Santi M
Acta Neuropathol Commun; 2019 Nov; 7(1):168. PubMed ID: 31685033
[TBL] [Abstract][Full Text] [Related]
45. Biological and clinical significance of somatic mutations in Langerhans cell histiocytosis and related histiocytic neoplastic disorders.
Allen CE; Parsons DW
Hematology Am Soc Hematol Educ Program; 2015; 2015():559-64. PubMed ID: 26637772
[TBL] [Abstract][Full Text] [Related]
46. Co-existence of BRAF V600E-mutated malignant melanoma and BRAF V600E-mutated Langerhans cell histiocytosis: A case report.
Goto K; Yoshikawa S; Kiyohara Y; Kukita Y; Miura K; Oishi T
J Cutan Pathol; 2022 Apr; 49(4):393-398. PubMed ID: 34792818
[TBL] [Abstract][Full Text] [Related]
47. Molecular analysis of BRAF V600E mutation in multiple nodules of pulmonary Langerhans cell histiocytosis.
Dimmler A; Geddert H; Werner M; Faller G
Virchows Arch; 2017 Apr; 470(4):429-435. PubMed ID: 28220299
[TBL] [Abstract][Full Text] [Related]
48. Mutually exclusive recurrent somatic mutations in MAP2K1 and BRAF support a central role for ERK activation in LCH pathogenesis.
Chakraborty R; Hampton OA; Shen X; Simko SJ; Shih A; Abhyankar H; Lim KP; Covington KR; Trevino L; Dewal N; Muzny DM; Doddapaneni H; Hu J; Wang L; Lupo PJ; Hicks MJ; Bonilla DL; Dwyer KC; Berres ML; Poulikakos PI; Merad M; McClain KL; Wheeler DA; Allen CE; Parsons DW
Blood; 2014 Nov; 124(19):3007-15. PubMed ID: 25202140
[TBL] [Abstract][Full Text] [Related]
49. BRAF-V600E expression in precursor versus differentiated dendritic cells defines clinically distinct LCH risk groups.
Berres ML; Lim KP; Peters T; Price J; Takizawa H; Salmon H; Idoyaga J; Ruzo A; Lupo PJ; Hicks MJ; Shih A; Simko SJ; Abhyankar H; Chakraborty R; Leboeuf M; Beltrão M; Lira SA; Heym KM; Bigley V; Collin M; Manz MG; McClain K; Merad M; Allen CE
J Exp Med; 2014 Apr; 211(4):669-83. PubMed ID: 24638167
[TBL] [Abstract][Full Text] [Related]
50. Localized Langerhans cell histiocytosis of the thymus with BRAF V600E mutation: a case report with immunohistochemical and genetic analyses.
Oishi N; Kondo T; Mochizuki K; Inoue T; Kasai K; Nakazawa T; Mitsumori T; Katoh R
Hum Pathol; 2014 Jun; 45(6):1302-5. PubMed ID: 24703101
[TBL] [Abstract][Full Text] [Related]
51. Cutaneous adverse events in children treated with vemurafenib for refractory BRAF
Tardieu M; Néron A; Duvert-Lehembre S; Amine Larabi I; Barkaoui M; Emile JF; Seigneurin A; Boralevi F; Donadieu J
Pediatr Blood Cancer; 2021 Sep; 68(9):e29140. PubMed ID: 34109735
[TBL] [Abstract][Full Text] [Related]
52. Detection of BRAF V600E mutation in radiological Langerhans cell histiocytosis-associated neurodegenerative disease using droplet digital PCR analysis.
Shimizu S; Sakamoto K; Kudo K; Morimoto A; Shioda Y
Int J Hematol; 2023 Jul; 118(1):119-124. PubMed ID: 37010809
[TBL] [Abstract][Full Text] [Related]
53. Somatic ARAF mutations in pediatric Langerhans cell histiocytosis: clinicopathologic, genetic and functional profiling.
Liu R; Guo Y; Han L; Feng S; Cao J; Sun Y; Cao Z; Cui X
Clin Exp Med; 2023 Dec; 23(8):5269-5279. PubMed ID: 37572153
[TBL] [Abstract][Full Text] [Related]
54. Recurrent BRAF mutations in Langerhans cell histiocytosis.
Badalian-Very G; Vergilio JA; Degar BA; MacConaill LE; Brandner B; Calicchio ML; Kuo FC; Ligon AH; Stevenson KE; Kehoe SM; Garraway LA; Hahn WC; Meyerson M; Fleming MD; Rollins BJ
Blood; 2010 Sep; 116(11):1919-23. PubMed ID: 20519626
[TBL] [Abstract][Full Text] [Related]
55. Impact of
Razanamahery J; Godot A; Leguy-Seguin V; Samson M; Audia S; Bonnotte B
Front Immunol; 2023; 14():1260193. PubMed ID: 37809108
[TBL] [Abstract][Full Text] [Related]
56. Vemurafenib provides a rapid and robust clinical response in pediatric Langerhans cell histiocytosis with the BRAF V600E mutation but does not eliminate low-level minimal residual disease per ddPCR using cell-free circulating DNA.
Evseev D; Kalinina I; Raykina E; Osipova D; Abashidze Z; Ignatova A; Mitrofanova A; Maschan A; Novichkova G; Maschan M
Int J Hematol; 2021 Dec; 114(6):725-734. PubMed ID: 34383272
[TBL] [Abstract][Full Text] [Related]
57. BRAFV600E mutation in cutaneous lesions of patients with adult Langerhans cell histiocytosis.
Varga E; Korom I; Polyánka H; Szabó K; Széll M; Baltás E; Bata-Csörgő Z; Kemény L; Oláh J
J Eur Acad Dermatol Venereol; 2015 Jun; 29(6):1205-11. PubMed ID: 25351766
[TBL] [Abstract][Full Text] [Related]
58. A circulating subset of BRAF
Poch R; Le Louet S; Hélias-Rodzewicz Z; Hachem N; Plat G; Barkaoui MA; Lapillonne H; Delhommeau F; Emile JF; Donadieu J; Héritier S
Br J Haematol; 2021 Aug; 194(4):745-749. PubMed ID: 34312844
[TBL] [Abstract][Full Text] [Related]
59. Prevalence of the
Stathi D; Yavropoulou MP; Allen CE; Abhyankar H; Scull B; Tsoli M; Andreakos E; Kaltsas G; Makras P
Pediatr Hematol Oncol; 2022 Sep; 39(6):540-548. PubMed ID: 35139731
[TBL] [Abstract][Full Text] [Related]
60. MAPK/ERK signal pathway alterations in patients with Langerhans Cell Histiocytosis.
Novosad O; Skrypets T; Pastushenko Y; Titorenko I; Martynchyk A; Skachkova O; Inomistova M; Gorbach A; Khranovska N; Kryachok I
Klin Onkol; 2018; 31(2):130-136. PubMed ID: 29708356
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
